For example, a brand-new category of synthetic peptides, better known as mini proteins, were developed by some scientists working at the Indian Institute of Science (IISc), Bangalore in June 2022.
For instance, Bruker Corp. launched the two new timsTOF instruments in June 2021
Protein Assays for Cancer Diagnosis
Opportunities for disease diagnosis, classification, and monitoring are provided by protein analysis. An assay must fulfil specific requirements in order to be therapeutically relevant. To begin with, it must be capable of detecting the desired protein or proteins. An assay also needs to be specific to the protein it is meant to detect in addition to being sensitive. These tests must also work with readily accessible patient samples in order to be effective. Additionally, laboratory staff must be properly trained to carry out these processes, and the assay's equipment must be easily obtainable in clinical settings. Moreover, assays must be efficient in terms of labor and cost, as well as robust enough to produce data that can be compared across laboratories and staff.
For instance, 99.4% specificity and 95.3% sensitivity were reported from a six marker ELISA developed for ovarian cancer.
Therefore, the increasing cancer cases across the globe and their detection can escalate the global protein assays market considerably.
Government Funding for Research in Proteomics
For example, Indian Council of Medical Research (ICMR), Government of India provided a funding to Institute of Bioinformatics (IOB) as well as ICMR-Regional Medical research Centre, NE region, Dibrugarh for a project named “Proteomics and biochemical analysis for identification of novel bio- markers for predicting pregnancy induced hypertension (PIH)In a health and demographic cohort from Dibrugarh.” The IOB will be conducting protein analysis of urine samples of pregnant women in distinctive trimesters. The chief aim of this project is to develop a protein marker for the timely detection of PIH.
the Clinical Proteomic Tumor Analysis Consortium (CPTAC) served as an inspiration for funding that was announced by the National Cancer Institute’s (NCI) Small Business Innovation Research (SBIR) Development Center in August 2020. The announcement calls for the development of high-throughput single-cell proteome discovery technologies. This opportunity aims to improve our understanding of how cancer begins and spreads while also facilitating the discovery of powerful cancer biomarkers and their clinical utilization on a micro-scale.
Genome Canada and Genome BC offered a funding amount of over 18 million for protein research in the year 2018.
These fundings can offer lucrative opportunities for the global protein assays market.
Recent Developments
- Amedical life science company, PerkinElmer, Inc. launched two assay kits namedhomogenous time-resolved fluorescence (HTRF) and AlphalLISA in April 2022.These kits are meant for a timely detection and quantification of Chinesehamster ovary (CHO) host cell protein (HCP) impurities.
- A proteomic platform, providing biological understanding forthe purpose of research and development to the pharmaceutical as well as diagnosticfirms was launched by a leading proteomics company, Biognosys in March 2022.
- Eli Lilly and Company acquired Protomer Technologies in July2021.
- GeoMx DSP Protein Assays was launched by NanoStringTechnologies, Inc., a biotech company in November 2020.
Market Segmentation
Global protein assays market is segmented on the basis of type, product, technology, application, end user, and region
Company Profiles
The major players in the global protein assays market are Becton Dickinson and Co, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc, Merck KGaA, Abcam PLC, PerkinElmer Inc., QIAGEN NV, Lonza Group AG, Bio-Techne Corp, Illumina Inc, among others.
Attribute | Details |
Base Year | 2022 |
Historical Years | 2018 – 2021 |
Estimated Year | 2023 |
Forecast Period | 2024 – 2028 |
Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered | Type Product Technology Application End User |
Regional Scope | Asia Pacific; Europe; North America; South America; Middle East & Africa |
Country Scope | China; India; Japan; South Korea; Australia; France; Germany; United Kingdom; Italy; Spain; United States; Mexico; Canada; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE |
Key Companies Profiled | Becton Dickinson and Co, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc, Merck KGaA, Abcam PLC, PerkinElmer Inc., QIAGEN NV, Lonza Group AG, Bio-Techne Corp, Illumina Inc. |
Customization Scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |